Suchergebnisse - (Person:"De Meyer, Sandra")

PubPharm (14)

1

Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials

enthalten in: Journal of medical virology | 2021

von Lathouwers, E. | Weinsteiger, S. | Baugh, B. | +5

2

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

enthalten in: AIDS research and human retroviruses | 2020

von Lathouwers, E. | Wong, E. | Brown, K. | +108

3

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

enthalten in: Journal of hepatology | 2015

von Lenz, O. | Verbinnen, T. | Fevery, B. | +8

4

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C

enthalten in: Gastroenterology | 2014

von Buti, M. | Agarwal, K. | Horsmans, Y. | +13

5

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2013

von Sullivan, J. | De Meyer, S. | Bartels, D. | +14

6

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure

enthalten in: Journal of hepatology | 2013

von Foster, G. | Zeuzem, S. | Andreone, P. | +12

CommentIn: J Hepatol. 2013 Jun;58(6):1259. - PMID 23376359

7

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

enthalten in: Antiviral therapy | 2013

von Lathouwers, E. | De La Rosa, G. | Van de Casteele, T. | +4

8

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure : results from the REALIZE trial

enthalten in: Hepatology (Baltimore, Md.) | 2012

von De Meyer, S. | Dierynck, I. | Ghys, A. | +8

9

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

enthalten in: Current HIV research | 2012

von Bánhegyi, D. | Katlama, C. | da Cunha, C. | +7

10

Telaprevir for retreatment of HCV infection

enthalten in: The New England journal of medicine | 2011

von Zeuzem, S. | Andreone, P. | Pol, S. | +123

CommentIn: J Hepatol. 2011 Dec;55(6):1457-60. - PMID 21835142